(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
9 September 2011 (09.09.2011)

PCT

(10) International Publication Number
WO 2011/109400 A2

(51) International Patent Classification:
A61K 39/395 (2006.01)

(21) International Application Number:
PCT/US2011/026689

(22) International Filing Date:
1 March 2011 (01.03.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

61/310,692	4 March 2010 (04.03.2010)	US
61/310,695	4 March 2010 (04.03.2010)	US
61/311,057	5 March 2010 (05.03.2010)	US

(71) Applicant *(for all designated States except US)*: **MACROGENICS,INC.** [US/US]; 1500 E. Gude Drive, Rockville, MD 20850 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **LOO, Deryk, T.** [CA/US]; 1509 Pine Knoll Drive, Belmont, CA 94402 (US). **HUANG, Ling** [US/US]; 8210 Moorland Lane, Bethesda, MD 20817 (US).

(74) Agent: **AUERBACH, Jeffrey, I.**; The Auerbach Law Firm, LLC, 2275 Research Blvd., Suite 500, Rockville, MD 20850 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

[Continued on next page]

(54) Title: ANTIBODIES REACTIVE WITH B7-H3, IMMUNOLOGICALLY ACTIVE FRAGMENTS THEREOF AND USES THEREOF




Figure 23

(57) Abstract: The present invention relates to antibodies and their fragments that are immunoreactive to the mammalian, and more particularly, the human B7-H3 receptor and to uses thereof, particularly in the treatment of cancer and inflammation. The invention thus particularly concerns humanized B7-H3- reactive antibodies and their immunoreactive fragments that are capable of mediating, and more preferably enhancing the activation of the immune system against cancer cells that are associated with a variety of human cancers.

WO 2011/109400 A2

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

— *with sequence listing part of description (Rule 5.2(a))*